`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_____________
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`QUALICAPS CO., LTD,
`Patent Owner
`
`____________
`
`IPR2017-00203
`Patent 6,649,180 B1
`____________
`
`
`JOINT MOTION TO SEAL
`
`
`
`
`
`
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`I.
`
`INTRODUCTION
`Patent Owner and Petitioner jointly move to seal evidence produced
`
`Joint Motion to Seal
`
`pursuant to the Board’s order on Petitioner’s motion for additional
`
`discovery. Paper 35, 8. In particular, Patent Owner was ordered to file and
`
`serve (a) the complete transcript of the deposition of Mr. Masaru Tanjoh
`
`taken by Petitioner on March 22, 2017 in related district court litigation, and
`
`(b) “the documents relating to the experiments, data, and statements in Mr.
`
`Tanjoh’s Declaration (Ex. 1010, 105–108) that were marked as exhibits” at
`
`the deposition. Id.
`
`II. CONFIDENTIALITY DESIGNATIONS FROM LITIGATION
`The confidentiality designations used in this proceeding reflect those
`
`defined in the protective order from the related district court litigation
`
`Allergan Sales, LLC, and Qualicaps Co., Ltd. v. Mylan Pharmaceuticals,
`
`Inc., et al., Case No. 2:15-cv-01740-JRG-RS (consolidated with Case No.
`
`2:15-cv-01741-JRG-RS for certain purposes), a copy of which is filed in this
`
`proceeding as Exhibit 2063.
`
`The “PROTECTIVE ORDER MATERIAL” designation is governed
`
`as follows from the district court litigation protective order:
`
`A Party shall designate documents, information or material as
`“CONFIDENTIAL” only upon a good faith belief that the
`
`1
`
`
`
`Joint Motion to Seal
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`
`documents, information or material contains confidential or
`proprietary information or trade secrets of the Party or a Third
`Party to whom the Party reasonably believes it owes an
`obligation of confidentiality with respect to such documents,
`information or material.
`Ex. 2063, 4–5.
`
`The “RESTRICTED – ATTORNEYS’ EYES ONLY” and
`
`“RESTRICTED – OUTSIDE ATTORNEYS’ EYES ONLY” designations
`
`are governed as follows from the district court litigation protective order:
`
`To the extent a producing Party believes that certain Protected
`Material qualifying to be designated CONFIDENTIAL is so
`sensitive that its dissemination deserves even further limitation,
`the producing Party may designate such Protected Material
`“RESTRICTED
`-- ATTORNEYS’ EYES ONLY” or
`“RESTRICTED - OUTSIDE ATTORNEYS’ EYES ONLY.”
`The designation of “RESTRICTED - OUTSIDE ATTORNEYS’
`EYES ONLY” shall be used for documents, information, or
`material relating to sales by Qualicaps Co., LTD and licensing
`agreement made by Qualicaps Co., LTD, including license
`agreements between Qualicaps Co. LTD and Warner Chilcott
`(US) and/or Warner Chilcott Co. and license agreements
`between Qualicaps Co. LTD and Teva Pharmaceuticals USA,
`Inc., as well as documents or information that a Party believes
`in good faith contains information the disclosure of which is
`
`2
`
`
`
`Joint Motion to Seal
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`
`highly likely to cause significant harm to an individual or to the
`business or competitive position of the Producing Party,
`including, for example, highly sensitive business and financial
`information, highly sensitive
`research and development
`information, unpublished patent applications, and information
`related to whether or when to commercialize or attempt to
`commercialize any drug product. For the avoidance of doubt, a
`Defendant’s Abbreviated New Drug Application (“ANDA”), a
`Plaintiff’s New Drug Application
`(“NDA”),
`FDA
`correspondence related to said ANDA or NDA, and other
`technical information shall be designated “RESTRICTED --
`ATTORNEYS’ EYES ONLY” not “RESTRICTED - OUTSIDE
`ATTORNEYS’ EYES ONLY.” Notwithstanding any other
`provision of this order, expert reports (and drafts of said expert
`reports that are in good faith intended to be served on an
`opposing party), pleadings or other documents served on either
`party (but not exhibits thereto containing RESTRICTED –
`OUTSIDE ATTORNEYS’ EYES ONLY Protected Material)
`shall not be designated RESTRICTED – OUTSIDE
`ATTORNEYS’ EYES ONLY.
`Ex. 2063, 5–6.
`
`III. DOCUMENTS SOUGHT TO BE SEALED
`A. Masaru Tanjoh March 22, 2017 Deposition Transcript
`The deposition transcript is submitted as IPR Exhibit No. 2064 in both
`
`redacted and non-redacted versions. Portions of the deposition transcript
`
`3
`
`
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`were designated with the following confidentiality designations:
`
`Joint Motion to Seal
`
`PROTECTIVE-ORDER MATERIAL: 35:6-39:17; 42:11-20;
`
`43:21-46:19; 47:6-53:5; 54:15-57:1; 57:18-60:4; 61:20-63:20; 78:18-
`
`95:14; 96:4-105:3; 111:20-129:2; 154:20-155:9; 156:3-157:2; 199:4-
`
`201:21; 208:17-209:15; 211:9-214:20; 216:15-221:22; 222:11-225:8;
`
`235:13-237:18; 238:21-239:18.
`
`RESTRICTED--ATTORNEYS’ EYES ONLY: 168:14-180:17;
`
`182:1-199:5; 203:2-207:1; 207:11-208:16; 214:21-216:14; 226:12-
`
`229:13; 237:19-238:10; 239:19-247:20.
`
`RESTRICTED--OUTSIDE ATTORNEYS’ EYES ONLY:
`
`129:3-131:20; 153:19-154:12; 157:3-22; 158:1-15; 159:5-9; 161:11-
`
`167:14; 225:9-226:11; 229:20-235:12.
`
`Each page of the deposition transcript containing material having a
`
`confidentiality designation has been marked with
`
`the highest-level
`
`designation of material on that page and redacted in the redacted version.
`
`B. Deposition Exhibits
`Petitioner asked the Patent Owner to produce the following deposition
`
`exhibits having confidentiality designations (“AEO” means “Attorneys’
`
`Eyes Only”):
`
`4
`
`
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`IPR
`exhibit
`no.
`2067
`
`Deposition
`exhibit No.
`
`13
`
`2068
`
`2069
`2070
`
`2071
`
`2072
`
`14
`
`15
`16
`
`17
`
`18
`
`Joint Motion to Seal
`
`Description
`
`Japanese document, Bates No.
`QCDELZ_00000146
`English document headed
`“Addendum,” Bates No.
`QCDELZ_00000261
`Handwritten notes dated 6/3/98 AEO
`Cover page titled “Hardcopy
`AEO
`1646,” with one page attached
`Japanese document, Bates Nos.
`QCDELZ_00000001
`to QCDELZ_00000012
`Cover page titled “Hardcopy
`0661,” with Bates Nos.
`QCDELZ_00000235 to
`QCDELZ_00000238 attached
`
`Confidentiality
`level designated
`in litigation
`AEO
`
`AEO
`
`AEO
`
`AEO
`
`Patent Owner disagrees with Petitioner’s assertion that these exhibits
`
`“relat[e] to the experiments, data, and statements” in Mr. Tanjoh’s
`
`prosecution history declaration but agrees to produce them in order not to
`
`prolong this discovery dispute. Patent Owner does not concede the
`
`admissibility of this evidence in the present proceeding. Patent Owner
`
`reserves the right to lodge objections against Petitioner’s use of this evidence.
`
`Because the entirety of each deposition exhibit listed above is sealed
`
`at the indicated confidentiality level, redacted versions would be devoid
`
`entirely of information, would serve no public purpose, and are not
`
`submitted.
`
`5
`
`
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`
`Joint Motion to Seal
`
`Protective Order
`C.
`The parties to this proceeding propose a protective order that is
`
`modified from the Board’s default protective order to add the additional
`
`confidentiality designations. The proposed modified protective order is filed
`
`as Exhibit 2073. A markup showing changes from the Board’s default
`
`protective order is filed as Exhibit 2074.
`
`IV. GOOD CAUSE EXISTS TO SEAL EVIDENCE
`Petitioner does not challenge Patent Owner’s confidentiality
`
`designations for purposes of the present proceeding. The parties stipulate
`
`for purposes of the present proceeding that Patent Owner complied with the
`
`conditions described above for making
`
`the various confidentiality
`
`designations for the deposition transcript and the deposition exhibits. These
`
`documents are sealed at the indicated confidentiality levels in the related
`
`district court litigation, and the parties agree that it is in the best interests of
`
`the parties concerned to maintain the status quo by sealing the same
`
`evidence to the same extent in the present proceeding. The parties stipulate
`
`on this basis that good cause exists to seal this evidence.
`
`V. CONCLUSION
`For the foregoing reasons, the parties ask the Board to grant the
`
`motion to seal.
`
`6
`
`
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`
`
`Dated: August 30, 2017
`
`Joint Motion to Seal
`
`Respectfully submitted,
`
` /Scott E. Kamholz/
`Jessica L. Parezo, Reg. No. 50,286
`Andrea G. Reister, Reg. No. 36,253
`Scott E. Kamholz, Reg. No. 48,543
`Michael N. Kennedy, pro hac vice
`Megan P. Keane, pro hac vice
`Covington & Burling LLP
`One CityCenter, 850 Tenth St., NW
`Washington DC 20001
`
`MaryAnne Armstrong, Reg. No. 40,069
`Lynde F. Herzbach, Reg. No. 74,886
`Birch, Stewart, Kolasch & Birch, LLP
`8110 Gatehouse Rd, Ste 100 East
`Falls Church VA 22042
`
`Counsel for Patent Owner
`
`
`
` //D. Clay Holloway w/e/p
`Mitchell G. Stockwell, Reg. No. 39,389
`D. Clay Holloway, Reg. No. 58,011
`Jonathan D. Olinger, pro hac vice
`Kilpatrick Townsend & Stockton LLP
`1100 Peachtree Street, Suite 2800
`Atlanta, GA 30309
`
`Counsel for Petitioner
`
`
`7
`
`
`
`IPR2017-00203
`Patent 6,649,180 B1
`
`
`
`CERTIFICATE OF SERVICE
`
`Joint Motion to Seal
`
`Pursuant to 37 C.F.R. § 42.6, I certify that on the date listed below, a
`
`copy of this paper was served on the petitioner at the address listed below by
`
`email to Mylan-WC-IPR@kilpatricktownsend.com on the following counsel
`
`of record for Petitioner:
`
`Mitchell G. Stockwell
`D. Clay Holloway
`Jonathan D. Olinger
`Kilpatrick Townsend & Stockton LLP
`1100 Peachtree Street, Suite 2800
`Atlanta, GA 30309
`
`
`
`
`
`Dated: August 30, 2017
`
`
`
` /Scott E. Kamholz/
`Scott E. Kamholz, Reg. No. 48,543
`
`
`
`
`
`
`
`8
`
`